Cipla Receives Final Approval for a Generic Version of Gilead’s Viread®
Cipla Receives Final Approval for Generic Viread® Tablets
Cipla Receives Final Approval for a Generic Version of Gilead’s Viread®
Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Tenofovir Disoproxil Fumarate Tablets, 300mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Gilead Sciences’ Viread® Tablets, 300mg.
Budget 2018: Pharma Companies Want A Push On Research, Innovation
Understanding depression and related symptoms keyto suicide prevention in SA
Cipla’s Digital Transformation Continues, Launches 2 Digital Education Platforms
Cipla Battles Perceptions In A New Campaign
Cipla launches Q-TIB globally, a novel fixed dose combination in a single tablet for T.B. prophylaxis in HIV
Cipla Receives Final Approval for Generic Dacogen®
